doi: 10.1016/0304-3940(93)90852-c.
The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase
Affiliations
- PMID:8152612
- DOI: 10.1016/0304-3940(93)90852-c
Item in Clipboard
The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase
A Clow et al. Neurosci Lett..
Display options
Format
Display options
Format
Abstract
It has previously been shown that both the dopamine receptor agonist, pergolide, and the monoamine oxidase inhibitor, (-)-deprenyl, can cause induction of CuZn superoxide dismutase in the rat striatum. We have now confirmed this effect of pergolide (0.04 mg/kg i.p.) as being localised to the striatum, but not the cerebellum, and shown it to take 3 weeks to develop. Furthermore, we have found that MDL 72974, a more specific monoamine oxidase inhibitor than (-)-deprenyl, failed to bring about such an induction either at a low selective monoamine oxidase B inhibitory dose, or at a higher non-selective dose.
Similar articles
- The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity.Thiffault C, Quirion R, Poirier J.Thiffault C, et al.Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):127-36. doi: 10.1016/s0169-328x(97)00135-6.Brain Res Mol Brain Res. 1997.PMID:9387872
- Pergolide can induce soluble superoxide dismutase in rat striata.Clow A, Hussain T, Glover V, Sandler M, Walker M, Dexter D.Clow A, et al.J Neural Transm Gen Sect. 1992;90(1):27-31. doi: 10.1007/BF01250515.J Neural Transm Gen Sect. 1992.PMID:1466876
- Design and early clinical evaluation of selective inhibitors of monoamine oxidase.Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.Palfreyman MG, et al.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87. doi: 10.1016/0278-5846(88)90092-9.Prog Neuropsychopharmacol Biol Psychiatry. 1988.PMID:3266532
- Effects of dopaminergic drugs on superoxide dismutase: implications for senescence.Glover V, Clow A, Sandler M.Glover V, et al.J Neural Transm Suppl. 1993;40:37-45.J Neural Transm Suppl. 1993.PMID:8294899Review.
- [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].Knoll J.Knoll J.Vopr Med Khim. 1997 Nov-Dec;43(6):482-93.Vopr Med Khim. 1997.PMID:9503565Review.Russian.
Cited by
- The putative neuroprotective role of dopamine agonists in Parkinson's disease.Grandas F.Grandas F.Neurotox Res. 2000;2(2-3):205-13. doi: 10.1007/BF03033794.Neurotox Res. 2000.PMID:16787841
- Strategies for the protection of dopaminergic neurons against neurotoxicity.Gerlach M, Double KL, Youdim MB, Riederer P.Gerlach M, et al.Neurotox Res. 2000;2(2-3):99-114. doi: 10.1007/BF03033788.Neurotox Res. 2000.PMID:16787835
- Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.Markham A, Benfield P.Markham A, et al.CNS Drugs. 1997 Apr;7(4):328-40. doi: 10.2165/00023210-199707040-00005.CNS Drugs. 1997.PMID:27520755
- Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.Muralikrishnan D, Ebadi M, Brown-Borg HM.Muralikrishnan D, et al.Neurochem Res. 2004 Feb;29(2):379-84. doi: 10.1023/b:nere.0000013740.53483.39.Neurochem Res. 2004.PMID:15002733
- Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.Perez-Lloret S, Rascol O.Perez-Lloret S, et al.CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000.CNS Drugs. 2010.PMID:20932066Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources